PMID- 35295169
OWN - NLM
STAT- MEDLINE
DCOM- 20220504
LR  - 20230721
IS  - 2040-2309 (Electronic)
IS  - 2040-2295 (Print)
IS  - 2040-2295 (Linking)
VI  - 2022
DP  - 2022
TI  - Effects of Endoscopic Sinus Surgery Combined with Budesonide Treatment on Nasal 
      Cavity Function and Serum Inflammatory Factors in Patients with Chronic 
      Sinusitis.
PG  - 4140682
LID - 10.1155/2022/4140682 [doi]
LID - 4140682
AB  - In this article, we have explored the effects of endoscopic sinus surgery 
      together with budesonide treatment on nasal function and serum inflammatory 
      factors on patients with chronic sinusitis. We retrospectively analyzed 120 
      patients with chronic sinusitis who were admitted to our hospital from March 2018 
      to March 2021 and were eligible for this study. They were separated into 2 groups 
      according to different treatments, that is, the control group (treated with 
      endoscopic surgery alone) of 58 cases and observation group (treated with 
      endoscopic sinus surgery combined with budesonide) with 62 cases. Treatment 
      efficacy, surgical status, overall symptom score before and after treatment, 
      nasal mucociliary clearance function, serum eosinophils (EOS), serum 
      immunoglobulin E (IgE), serum inflammatory factors, and occurrence of adverse 
      reactions of both groups were recorded and compared. Total effective rate in the 
      observation group presented strikingly more positive compared with that among 
      patients in control group (P<0.05), as well as the data recorded in terms of 
      operation time, blood loss during surgery and postoperative improvement time of 
      patients (P<0.05). Overall symptom score, nasal mucociliary clearance, EOS, IgE 
      and serum inflammatory factors in both groups were improved notably after 
      treatment, while the observation group held a more obvious improvement. And it 
      also had a markedly lower incidence of adverse reaction (P<0.05). Endoscopic 
      sinus surgery combined with budesonide in the treatment of chronic sinusitis 
      could effectively improve the clinical symptoms of patients, reestablish the 
      function of the nasal cavity and improve their inflammation level. Meanwhile, it 
      was of high safety and is worthy of clinical promotion.
CI  - Copyright (c) 2022 Yingying Zhao et al.
FAU - Zhao, Yingying
AU  - Zhao Y
AD  - Department of Ortolaryngology, Huangpu Branch, Shanghai Ninth People's Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai,200011, China.
FAU - Jiang, Chenyan
AU  - Jiang C
AD  - Department of Ortolaryngology, Shanghai Ninth People's Hospital, Shanghai Jiao 
      Tong University School of Medicine, Shanghai 200011, China.
FAU - Wu, Qingwei
AU  - Wu Q
AD  - Department of Ortolaryngology, Shanghai Ninth People's Hospital, Shanghai Jiao 
      Tong University School of Medicine, Shanghai 200011, China.
FAU - Shi, Runjie
AU  - Shi R
AUID- ORCID: 0000-0001-8068-4534
AD  - Department of Ortolaryngology, Shanghai Ninth People's Hospital, Shanghai Jiao 
      Tong University School of Medicine, Shanghai 200011, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Retracted Publication
DEP - 20220307
PL  - England
TA  - J Healthc Eng
JT  - Journal of healthcare engineering
JID - 101528166
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 51333-22-3 (Budesonide)
SB  - IM
RIN - J Healthc Eng. 2023 Jul 12;2023:9763868. PMID: 37476792
MH  - Budesonide/therapeutic use
MH  - Chronic Disease
MH  - Endoscopy
MH  - Humans
MH  - Immunoglobulin E/therapeutic use
MH  - Inflammation/drug therapy
MH  - *Nasal Cavity
MH  - Retrospective Studies
MH  - *Sinusitis/drug therapy/surgery
PMC - PMC8920662
COIS- The authors declare that there are no conflicts of interest regarding the 
      publication of this paper.
EDAT- 2022/03/18 06:00
MHDA- 2022/05/06 06:00
PMCR- 2022/03/07
CRDT- 2022/03/17 05:05
PHST- 2021/12/08 00:00 [received]
PHST- 2022/01/06 00:00 [revised]
PHST- 2022/01/19 00:00 [accepted]
PHST- 2022/03/17 05:05 [entrez]
PHST- 2022/03/18 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2022/03/07 00:00 [pmc-release]
AID - 10.1155/2022/4140682 [doi]
PST - epublish
SO  - J Healthc Eng. 2022 Mar 7;2022:4140682. doi: 10.1155/2022/4140682. eCollection 
      2022.